Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Redo-Transcatheter Aortic Valve Implantation (Redo-TAVI)-Pilot Study from Multicentre Nationwide Registry.

Journal of clinical medicine·2025
Same author

Treatment of Severe Tricuspid Regurgitation with the TricValve System Implantation-Preliminary Results of a Prospective Registry.

Journal of clinical medicine·2025
Same author

Vessel-Specific Myocardial Mass in Patients With Stable Coronary Artery Disease.

Journal of the American Heart Association·2025
Same author

Ischemic Complications in a Patient With Spontaneous Echo Contrast Undergoing Percutaneous Left Atrial Appendage Closure.

JACC. Case reports·2025
Same author

Cost-utility analysis of the use of a wearable cardioverter defibrillator (LifeVest®) versus standard of care in the prevention of sudden cardiac death in patients after myocardial infarction.

Kardiologia polska·2025
Same author

Cardiology in Poland: A report for the year 2024 - part 2: Electrophysiology and device therapy.

Kardiologia polska·2025

Related Experiment Video

Updated: Jul 9, 2026

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

3.7K

Mitral Valve Transcatheter Edge-to-Edge Repair: 1-Year Outcomes From the MiCLASP Study.

Philipp Lurz1, Thomas Schmitz2, Tobias Geisler3

  • 1Department of Cardiology, University Medical Center Mainz, Mainz, Germany.

JACC. Cardiovascular Interventions
|April 10, 2024
PubMed
Summary

Mitral transcatheter edge-to-edge repair (M-TEER) using the PASCAL system shows strong 1-year safety and effectiveness in a real-world setting. This treatment significantly reduces mitral regurgitation and improves patient survival and quality of life.

Keywords:
M-TEERMiCLASPPASCALmitral regurgitationpost-market

More Related Videos

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

3.9K
Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
08:12

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels

Published on: May 26, 2023

1.6K

Related Experiment Videos

Last Updated: Jul 9, 2026

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

3.7K
A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

3.9K
Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
08:12

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels

Published on: May 26, 2023

1.6K

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Medical Devices

Background:

  • Mitral transcatheter edge-to-edge repair (M-TEER) is a recommended treatment for severe symptomatic mitral regurgitation (MR).
  • Real-world outcomes for the PASCAL system post-market have not been extensively documented.

Purpose of the Study:

  • To evaluate the 30-day and 1-year safety and effectiveness of the PASCAL system for M-TEER.
  • To assess clinical, echocardiographic, functional, and quality-of-life outcomes in a European post-market study.

Main Methods:

  • Prospective enrollment of 544 patients with symptomatic, clinically significant MR.
  • Primary safety endpoint: 30-day composite major adverse event rate.
  • Primary effectiveness endpoint: MR severity at discharge vs. baseline, assessed by echocardiography.

Main Results:

  • The 30-day major adverse event rate was 6.8%.
  • At 1 year, 98% of patients had MR ≤2+ and 82.6% had MR ≤1+.
  • Survival was 87.3%, and freedom from heart failure hospitalization was 84.3% at 1 year.

Conclusions:

  • The MiCLASP study confirms the safety and effectiveness of M-TEER with the PASCAL system in a post-market setting.
  • The PASCAL system demonstrated high survival, reduced heart failure hospitalizations, and improved patient functional capacity and quality of life.